폐암용 면역관문 억제제 시장 - 세계 예측(2026-2032년)

The Immune Checkpoint Inhibitors for Lung Cancer Market is projected to grow by USD 3.55 billion at a CAGR of 15.08% by 2032.

Immune checkpoint inhibitors for lung cancer have become a central pillar of modern oncology, particularly for non-small cell lung cancer and selected small cell lung cancer settings. By targeting inhibitory pathways such as PD-1, PD-L1, and CTLA-4, these immunotherapies help restore anti-tumor T-cell activity and have reshaped treatment strategies across first-line, maintenance, consolidation, perioperative, and recurrent disease pathways. Clinical adoption is closely linked to biomarker testing, including PD-L1 expression, tumor mutational burden in selected contexts, microsatellite instability status, and broader molecular profiling to distinguish patients who may benefit from immunotherapy alone, chemo-immunotherapy, dual immunotherapy, or targeted therapy sequencing.

The lung cancer immunotherapy landscape is increasingly defined by evidence-based personalization. Regulatory approvals and clinical guidelines have expanded the role of checkpoint blockade across metastatic disease, unresectable stage III disease following chemoradiation, and resectable tumors before or after surgery. At the same time, clinicians and health systems are balancing durable response potential with immune-related adverse event management, steroid-sparing toxicity protocols, real-world patient eligibility, and equitable access to diagnostic infrastructure. As survival gains become more dependent on precision selection and multidisciplinary care, immune checkpoint inhibitors remain a high-priority area for clinical development, payer evaluation, and oncology service redesign.

Transformative Shifts in Lung Cancer Immunotherapy

The landscape for immune checkpoint inhibitors in lung cancer is undergoing transformative shifts driven by earlier-stage use, combination regimens, and deeper biomarker integration. Immunotherapy is no longer confined to advanced metastatic settings; peer-reviewed clinical evidence has supported its movement into neoadjuvant, adjuvant, and consolidation strategies, creating new decision points for thoracic surgeons, medical oncologists, radiation oncologists, pathologists, and payers. This shift is increasing the importance of coordinated diagnostic pathways that can deliver timely PD-L1 testing, next-generation sequencing, and pathology review before treatment initiation.

Combination approaches are also redefining standards of care. Chemo-immunotherapy has broadened eligibility for patients with varied PD-L1 expression, while dual-checkpoint strategies and immunotherapy combined with anti-angiogenic agents are being evaluated for selected patient profiles. Another major shift is the intensified focus on resistance biology, including primary resistance, acquired resistance, immune-excluded tumors, oncogene-driven lung cancers with lower immunotherapy responsiveness, and the tumor microenvironment. These dynamics are prompting clinical research into novel checkpoint targets, rational sequencing, treatment de-escalation in selected responders, and toxicity-reduction strategies.

Operationally, oncology systems are adapting to longer treatment journeys, survivorship needs, immune-related adverse event surveillance, and real-world evidence collection. Digital pathology, decentralized sample logistics, multidisciplinary tumor boards, and harmonized biomarker reporting are becoming critical enablers of high-quality immunotherapy delivery. The result is a more complex but more precise lung cancer care ecosystem in which clinical efficacy, diagnostic readiness, reimbursement governance, and safety monitoring must advance together.

Cumulative Impact of Artificial Intelligence on Checkpoint Inhibitor Care

Artificial intelligence is creating cumulative impact across the immune checkpoint inhibitor pathway for lung cancer, from early diagnosis and treatment selection to toxicity monitoring and real-world evidence generation. In imaging, AI-assisted radiomics is being investigated to extract quantitative features from CT, PET, and MRI scans that may correlate with tumor biology, response patterns, pseudoprogression, hyperprogression, and disease progression. In pathology, AI-enabled image analysis can support reproducible PD-L1 scoring workflows, tumor-infiltrating lymphocyte assessment, and tissue prioritization for molecular testing, while still requiring expert clinical validation and regulatory-grade quality controls.

AI is also improving the integration of complex multimodal data. Lung cancer treatment decisions increasingly depend on combining histology, smoking history, stage, PD-L1 status, genomic alterations, prior therapies, comorbidities, performance status, and laboratory parameters. Machine learning models can help identify patterns in electronic health records and clinical datasets that inform patient stratification, trial matching, and adverse event prediction. Natural language processing can further structure unstandardized oncology notes, radiology impressions, pathology reports, and immune-related toxicity documentation.

The most immediate value of AI lies in workflow acceleration and clinical decision support rather than autonomous treatment selection. Responsible deployment requires transparent algorithms, representative datasets, bias monitoring, interoperability with oncology information systems, cybersecurity safeguards, and evidence of clinical utility. As health systems adopt AI to support lung cancer immunotherapy, the strongest outcomes are expected where AI tools are embedded into biomarker-driven care pathways, multidisciplinary review, pharmacovigilance, and patient monitoring programs.

Key Regional Insights Across Global Lung Cancer Immunotherapy

Asia-Pacific is experiencing rapid evolution in immune checkpoint inhibitors for lung cancer due to a high lung cancer burden, expanding oncology infrastructure, and increased adoption of biomarker testing in major health systems. China, Japan, South Korea, India, and Australia are advancing clinical use through regulatory approvals, domestic clinical research, and broader hospital-based molecular diagnostics. Access remains heterogeneous, with urban cancer centers often offering more comprehensive immunotherapy services than rural or resource-constrained settings, making diagnostic scale-up and reimbursement clarity central to regional progress.

North America remains a highly developed region for lung cancer immunotherapy, supported by guideline-driven treatment pathways, extensive biomarker testing capacity, active clinical trial networks, and strong pharmacovigilance systems. The United States and Canada have integrated checkpoint inhibitors across multiple stages of non-small cell lung cancer, with growing emphasis on real-world outcomes, health equity, and toxicity management models. Reimbursement requirements, prior authorization processes, and variability in molecular testing coverage continue to shape treatment timeliness and patient access.

Latin America is advancing adoption of immune checkpoint inhibitors through improving cancer diagnostics, public-private oncology initiatives, and increasing specialist awareness. Brazil and Mexico are important regional centers for oncology care and clinical research; however, access to PD-L1 testing, next-generation sequencing, and immunotherapy reimbursement varies significantly by payer type, geography, and treatment setting. This creates a dual challenge of improving diagnostic equity and strengthening evidence-based access pathways.

Europe demonstrates broad clinical integration of checkpoint inhibitors, supported by centralized regulatory evaluation, national health technology assessments, and mature oncology guideline systems. Countries across Western Europe have incorporated immunotherapy into lung cancer standards, while Central and Eastern European access can be influenced by reimbursement timing, testing infrastructure, and national budget priorities. The region is also emphasizing real-world evidence, sustainable oncology spending, and harmonization of biomarker quality standards.

The Middle East is expanding advanced lung cancer treatment capabilities through investment in tertiary cancer centers, specialist training, and precision oncology programs, particularly in Gulf health systems. Access to checkpoint inhibitors is improving in major metropolitan centers, while regional disparities persist in diagnostic coverage and oncology workforce availability. Africa faces the greatest access constraints, with late-stage diagnosis, limited pathology capacity, uneven availability of PD-L1 testing, and affordability barriers affecting immunotherapy use. Across the continent, priorities include strengthening cancer registries, pathology networks, essential diagnostics, referral systems, and participation in context-appropriate clinical research.

Key Group Insights Across ASEAN, GCC, EU, BRICS, G7, and NATO

ASEAN countries are increasingly incorporating immune checkpoint inhibitors for lung cancer into tertiary oncology practice, although access differs widely between higher-resource urban centers and lower-resource provincial systems. Singapore, Thailand, Malaysia, Indonesia, Vietnam, and the Philippines show varying levels of diagnostic readiness, reimbursement maturity, and clinical trial participation. The region's core opportunity lies in improving standardized PD-L1 testing, expanding pathology capacity, and building referral pathways for advanced lung cancer management.

The GCC is progressing rapidly in precision oncology, supported by investment in specialist hospitals, national cancer strategies, and adoption of advanced therapeutics in countries with strong healthcare funding capacity. Lung cancer immunotherapy uptake is closely linked to centralized procurement, access to companion diagnostics, and the availability of multidisciplinary oncology teams. Regional priorities include improving screening awareness, capturing real-world outcomes, and developing immune-related adverse event protocols across institutions.

The European Union provides a structured environment for immune checkpoint inhibitor adoption through coordinated regulatory assessment, national reimbursement reviews, and guideline-based cancer care. While clinical standards are increasingly aligned, patient access timelines and biomarker testing reimbursement still vary among member states. EU-level emphasis on health data interoperability, cancer initiatives, and cross-border research collaboration supports continued improvement in lung cancer immunotherapy evidence generation.

BRICS countries represent a diverse group with large patient populations, expanding oncology capabilities, and significant variability in access. China has become a major contributor to lung cancer immunotherapy research and approvals, India is expanding access through oncology networks and molecular diagnostics growth, Brazil and Russia continue to balance reimbursement and infrastructure challenges, and South Africa faces access constraints linked to diagnostic and funding limitations. Across BRICS, scalable biomarker testing, local clinical evidence, and affordable care delivery are central to broader adoption.

G7 countries generally demonstrate advanced clinical integration of checkpoint inhibitors, supported by mature regulatory systems, sophisticated diagnostics, and active cancer research ecosystems. The group is increasingly focused on optimizing treatment duration, managing financial toxicity, improving inclusion of older adults and comorbid patients, and using real-world evidence to refine clinical practice. NATO countries overlap substantially with high-income oncology systems in North America and Europe, but also include members with varied reimbursement capacity and infrastructure maturity. Within this group, the emphasis is on healthcare resilience, secure medical supply chains, interoperable health data, and maintaining access to advanced cancer care during system disruptions.

Key Country Insights for Lung Cancer Checkpoint Inhibitors

The United States has deeply integrated immune checkpoint inhibitors into lung cancer care through guideline-based use, comprehensive biomarker testing, broad clinical trial activity, and established immune-related toxicity management. Canada follows a publicly funded oncology model where provincial reimbursement decisions, centralized cancer agencies, and biomarker access influence treatment consistency. Mexico is expanding immunotherapy availability in private and selected public settings, though diagnostic access and affordability remain important barriers.

Brazil is the leading Latin American country for advanced oncology adoption, with growing use of checkpoint inhibitors in major cancer centers and ongoing challenges related to public system reimbursement and molecular testing access. The United Kingdom has incorporated lung cancer immunotherapy through national evaluation frameworks, rapid cancer diagnostic pathways, and real-world evidence programs. Germany benefits from strong specialist care, pathology infrastructure, and biomarker testing capacity, while France emphasizes national oncology planning, structured reimbursement evaluation, and multidisciplinary cancer care.

Russia has clinical expertise in oncology and access to immunotherapy in selected settings, but regional variation in diagnostics and reimbursement can affect patient pathways. Italy and Spain have integrated checkpoint inhibitors across lung cancer indications through national and regional health systems, with ongoing attention to treatment appropriateness, budget governance, and equitable biomarker testing. China has rapidly advanced lung cancer immunotherapy through domestic clinical research, expanding approvals, and growth in hospital-based precision medicine, while managing large-scale access and reimbursement complexity.

India is seeing increased adoption in major metropolitan oncology centers, supported by growing molecular diagnostics and specialist expertise, but out-of-pocket costs and uneven diagnostic infrastructure limit broad access. Japan has extensive clinical experience with checkpoint inhibitors, mature pharmacovigilance, and strong guideline adherence, with careful attention to immune-related adverse events in an aging population. Australia combines strong oncology networks, public reimbursement mechanisms, and clinical trial participation to support evidence-based immunotherapy access. South Korea has advanced cancer centers, high diagnostic sophistication, and active research in lung cancer immunotherapy, with payer policies and biomarker criteria shaping real-world utilization.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence-based differentiation by aligning clinical development, diagnostic partnerships, and patient access strategies around biomarker-defined lung cancer populations. Investment in high-quality PD-L1 testing, next-generation sequencing workflows, liquid biopsy validation, and standardized pathology reporting can reduce treatment delays and improve therapeutic precision. Clinical programs should continue to address unmet needs in early-stage lung cancer, resistance after checkpoint inhibitor exposure, oncogene-driven tumors, elderly patients, patients with autoimmune comorbidities, and populations underrepresented in trials.

Commercial and medical affairs teams should strengthen education around immune-related adverse event recognition, multidisciplinary management, and treatment sequencing. Collaboration with health systems can support infusion capacity planning, toxicity triage pathways, survivorship monitoring, and real-world data capture. Access strategies should be tailored to local reimbursement environments and should include diagnostic funding solutions, outcomes evidence, and support for equitable patient identification.

Technology leaders should focus on clinically validated AI and digital tools that improve workflow efficiency, trial matching, imaging assessment, pathology consistency, and remote symptom monitoring. Regulatory, medical, and market access teams must ensure that claims are supported by robust clinical evidence, real-world validation, and transparent safety reporting. The organizations best positioned in lung cancer immunotherapy will be those that integrate therapeutic innovation with diagnostic readiness, patient-centered care delivery, and measurable real-world value.

Research Methodology

This executive summary is developed using a structured secondary research methodology focused on verified, data-backed sources relevant to immune checkpoint inhibitors for lung cancer. The research approach includes review of peer-reviewed oncology literature, regulatory documents, clinical practice guidelines, health technology assessments, public health publications, clinical trial registries, cancer agency resources, and pharmacovigilance references. Evidence is prioritized from authoritative sources such as national and international oncology guidelines, regulatory labels, major medical journals, cancer registries, and public health institutions.

The methodology emphasizes qualitative synthesis rather than market sizing or forecasting. Key themes are assessed across clinical utility, treatment pathways, biomarker requirements, safety considerations, regional access dynamics, healthcare infrastructure, and emerging technology integration. Regional, group, and country insights are interpreted through available evidence on lung cancer burden, diagnostic capacity, reimbursement structures, clinical adoption patterns, health system maturity, and oncology workforce availability.

To maintain reliability, findings are cross-checked across multiple credible sources where possible, and claims are framed conservatively when evidence varies by jurisdiction or patient subgroup. The analysis excludes speculative estimates and avoids unsupported commercial assumptions. The resulting summary is designed to support strategic understanding of the immune checkpoint inhibitor landscape while remaining grounded in validated clinical and healthcare-system evidence.

Conclusion

Immune checkpoint inhibitors have fundamentally changed lung cancer treatment by enabling durable responses for selected patients and expanding therapeutic options across disease stages. Their continued impact depends on precise patient selection, timely biomarker testing, effective management of immune-related adverse events, and equitable access to advanced diagnostics and oncology expertise. The field is moving toward earlier intervention, rational combinations, improved resistance management, and broader use of real-world evidence to refine clinical practice.

Regional and country-level adoption patterns show that scientific progress alone is not sufficient; outcomes also depend on reimbursement structures, pathology capacity, oncology workforce availability, and care coordination. Artificial intelligence and digital health tools offer meaningful support for imaging, pathology, patient monitoring, and evidence generation, but their value will depend on validation, transparency, and integration into clinical workflows.

For stakeholders across the lung cancer immunotherapy ecosystem, the strategic imperative is clear: align innovation with diagnostics, safety, access, and real-world performance. Organizations that build scalable, evidence-driven, and patient-centered models will be better positioned to support the next phase of immune checkpoint inhibitor use in lung cancer care.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. New Revenue Opportunities
• 3.5. Next-Generation Business Models
• 3.6. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Immune Checkpoint Inhibitors for Lung Cancer Market, by Type

• 7.1. Introduction
• 7.2. PD-1 Inhibitors
• 7.3. PD-L1 Inhibitors
• 7.4. CTLA-4 Inhibitors

8. Immune Checkpoint Inhibitors for Lung Cancer Market, by Treatment Regimen

• 8.1. Introduction
• 8.2. Combination Therapy
  • 8.2.1. With Chemotherapy
  • 8.2.2. With Targeted Therapy
• 8.3. Monotherapy

9. Immune Checkpoint Inhibitors for Lung Cancer Market, by Line Of Therapy

• 9.1. Introduction
• 9.2. First Line
• 9.3. Second Line
• 9.4. Third Or Later

10. Immune Checkpoint Inhibitors for Lung Cancer Market, by Distribution Channel

• 10.1. Introduction
• 10.2. Hospital Pharmacy
• 10.3. Online Pharmacy
• 10.4. Retail Pharmacy
• 10.5. Specialty Pharmacy

11. Immune Checkpoint Inhibitors for Lung Cancer Market, by End User

• 11.1. Introduction
• 11.2. Ambulatory Surgical Centers
• 11.3. Home Care Settings
• 11.4. Hospitals
• 11.5. Oncology Clinics

12. Immune Checkpoint Inhibitors for Lung Cancer Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Immune Checkpoint Inhibitors for Lung Cancer Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Immune Checkpoint Inhibitors for Lung Cancer Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Share Analysis, 2025
• 15.2. FPNV Positioning Matrix, 2025
• 15.3. Market Concentration Analysis, 2025
  • 15.3.1. Concentration Ratio (CR)
  • 15.3.2. Herfindahl Hirschman Index (HHI)
• 15.4. Recent Developments & Impact Analysis, 2025
• 15.5. Product Portfolio Analysis, 2025
• 15.6. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. AstraZeneca plc
• 16.2. Bristol-Myers Squibb Company
• 16.3. Celgene Corporation
• 16.4. F. Hoffmann-La Roche AG
• 16.5. Genentech, Inc.
• 16.6. Innovent Biologics, Inc.
• 16.7. Lepu Biopharma Co., Ltd.
• 16.8. Merck & Co.
• 16.9. Ono Pharmaceutical Co. Ltd
• 16.10. Regeneron Pharmaceuticals
• 16.11. Shanghai Junshi Biosciences Co. Ltd.